Details for New Drug Application (NDA): 213463
✉ Email this page to a colleague
NDA 213463 describes DACTINOMYCIN, which is a drug marketed by Am Regent, Eugia Pharma, Hikma, Hisun Pharm Hangzhou, Meitheal, and Xgen Pharms, and is included in six NDAs. It is available from four suppliers. Additional details are available on the DACTINOMYCIN profile page.
The generic ingredient in DACTINOMYCIN is dactinomycin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dactinomycin profile page.
The generic ingredient in DACTINOMYCIN is dactinomycin. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dactinomycin profile page.
Summary for 213463
| Tradename: | DACTINOMYCIN |
| Applicant: | Meitheal |
| Ingredient: | dactinomycin |
| Patents: | 0 |
Pharmacology for NDA: 213463
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors Protein Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 213463
Suppliers and Packaging for NDA: 213463
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 213463 | ANDA | Meitheal Pharmaceuticals Inc. | 71288-129 | 71288-129-02 | 1 VIAL, SINGLE-DOSE in 1 CARTON (71288-129-02) / 1 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 0.5MG/VIAL | ||||
| Approval Date: | Nov 13, 2020 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
